23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › United Therapeutics Corporation › 2025-2026

United Therapeutics Corporation 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and United Therapeutics Corporation’s Form 8-K, filed June 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 15Ballot items
  • 708Asset managers, any item
  • 11,575Fund votes
  • June 26, 2026Meeting date

Results at a glance

Meeting of June 26, 2026: 15 items on United Therapeutics Corporation’s Form 8-K, filed June 29, 2026: 15 passed (calculated).

Dissent

Significant dissent: 1 equity or compensation plan (28.0% against).

Notable dissent: 1 director (10.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore United Therapeutics Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by United Therapeutics Corporation

These tallies are United Therapeutics Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

United Therapeutics Corporation — official shareholder meeting results, meeting held June 26, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Christopher Causey 32,342,9833,861,56614,328 --1,194,857 89%Passed (calculated)—
Elect Director: Richard Giltner 33,029,8283,174,66214,387 --1,194,857 91%Passed (calculated)—
Elect Director: Ray Kurzweil 35,215,793988,97914,105 --1,194,857 97%Passed (calculated)—
Elect Director: Jan Malcolm 35,912,588292,98113,308 --1,194,857 99.2%Passed (calculated)—
Elect Director: Linda Maxwell 35,472,607725,97720,293 --1,194,857 98%Passed (calculated)—
Elect Director: Nilda Mesa 35,477,452715,17426,251 --1,194,857 98%Passed (calculated)—
Elect Director: Judy Olian 35,661,334543,34314,200 --1,194,857 98%Passed (calculated)—
Elect Director: Christopher Patusky 32,649,2923,555,21914,366 --1,194,857 90%Passed (calculated)—
Elect Director: Martine Rothblatt 34,492,9741,713,78912,114 --1,194,857 95%Passed (calculated)—
Elect Director: Louis Sullivan 33,409,6072,794,33214,938 --1,194,857 92%Passed (calculated)—
Elect Director: Tommy Thompson 35,012,7861,192,15513,936 --1,194,857 97%Passed (calculated)—
Elect Director: Kevin Tracey 36,187,55418,23913,084 --1,194,857 99.9%Passed (calculated)—
2. Advisory resolution to approve executive compensation 35,152,0591,048,50518,313 --1,194,857 97%Passed (calculated)—
3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan 25,872,07510,070,290276,512 --1,194,857 72%Passed (calculated)—
4. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026 35,753,8871,647,41512,432 ---- 96%Passed (calculated)—

Source: United Therapeutics Corporation, Form 8-K, filed with the SEC on June 29, 2026 — read the filing on EDGAR.

How asset managers voted at the United Therapeutics Corporation 2025-2026 meeting

708 asset managers disclosed a vote on at least one United Therapeutics Corporation item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Christopher Causey

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 32,342,983AGAINST: 3,861,566

Prior year: 86.8% for (June 26, 2025 meeting) ▲ 2.5 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Christopher Causey

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Causey”): 32,342,983 for, 3,861,566 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 14,356,801 for, 839,329 against, 9,058 abstained, 55 not voted.

FOR
FOR: 14,356,801AGAINST: 839,329ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Christopher Causey” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,078,1663,197 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street1,733487,778 00Against
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA0155,920 00Against
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National7,42874,136 00Mixed
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Christopher Patusky

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 32,649,292AGAINST: 3,555,219

Prior year: 88.6% for (June 26, 2025 meeting) ▲ 1.6 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Christopher Patusky

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Patusky”): 32,649,292 for, 3,555,219 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 14,662,623 for, 533,506 against, 9,058 abstained, 55 not voted.

FOR
FOR: 14,662,623AGAINST: 533,506ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Christopher Patusky” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,35012 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street1,733487,778 00Against
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Jan Malcolm

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 35,912,588AGAINST: 292,981

Prior year: 98.8% for (June 26, 2025 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Jan Malcolm

United Therapeutics Corporation’s own tally for this item (“Elect Director: Jan Malcolm”): 35,912,588 for, 292,981 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,191,449 for, 4,681 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,191,449AGAINST: 4,681ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Jan Malcolm” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3621 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,5110 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Judy Olian

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 35,661,334AGAINST: 543,343

Prior year: 99.1% for (June 26, 2025 meeting) ▼ 0.6 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Judy Olian

United Therapeutics Corporation’s own tally for this item (“Elect Director: Judy Olian”): 35,661,334 for, 543,343 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,180,218 for, 15,912 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,180,218AGAINST: 15,912ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Judy Olian” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3612 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,48724 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Kevin Tracey

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 36,187,554AGAINST: 18,239
Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Kevin Tracey

United Therapeutics Corporation’s own tally for this item (“Elect Director: Kevin Tracey”): 36,187,554 for, 18,239 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,191,450 for, 4,680 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,191,450AGAINST: 4,680ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Kevin Tracey” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3630 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,5110 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Linda Maxwell

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 35,472,607AGAINST: 725,977

Prior year: 98.8% for (June 26, 2025 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Linda Maxwell

United Therapeutics Corporation’s own tally for this item (“Elect Director: Linda Maxwell”): 35,472,607 for, 725,977 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,173,123 for, 23,007 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,173,123AGAINST: 23,007ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Linda Maxwell” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3612 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,5110 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Louis Sullivan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 33,409,607AGAINST: 2,794,332

Prior year: 90.4% for (June 26, 2025 meeting) ▲ 1.9 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Louis Sullivan

United Therapeutics Corporation’s own tally for this item (“Elect Director: Louis Sullivan”): 33,409,607 for, 2,794,332 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 14,679,723 for, 516,407 against, 9,058 abstained, 55 not voted.

FOR
FOR: 14,679,723AGAINST: 516,407ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Louis Sullivan” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,35211 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street1,733487,778 00Against
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Martine Rothblatt

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 34,492,974AGAINST: 1,713,789

Prior year: 93.7% for (June 26, 2025 meeting) ▲ 1.6 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Martine Rothblatt

United Therapeutics Corporation’s own tally for this item (“Elect Director: Martine Rothblatt”): 34,492,974 for, 1,713,789 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,140,493 for, 55,637 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,140,493AGAINST: 55,637ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Martine Rothblatt” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3576 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,48724 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock99,58935,121 00Mixed
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Nilda Mesa

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 35,477,452AGAINST: 715,174

Prior year: 97.9% for (June 26, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Nilda Mesa

United Therapeutics Corporation’s own tally for this item (“Elect Director: Nilda Mesa”): 35,477,452 for, 715,174 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,173,123 for, 23,007 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,173,123AGAINST: 23,007ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Nilda Mesa” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3612 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,5110 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Ray Kurzweil

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 35,215,793AGAINST: 988,979

Prior year: 95.4% for (June 26, 2025 meeting) ▲ 1.8 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Ray Kurzweil

United Therapeutics Corporation’s own tally for this item (“Elect Director: Ray Kurzweil”): 35,215,793 for, 988,979 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,188,903 for, 7,227 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,188,903AGAINST: 7,227ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Ray Kurzweil” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3594 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,48724 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Richard Giltner

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 33,029,828AGAINST: 3,174,662

Prior year: 94.5% for (June 26, 2025 meeting) ▼ 3.2 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Richard Giltner

United Therapeutics Corporation’s own tally for this item (“Elect Director: Richard Giltner”): 33,029,828 for, 3,174,662 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 14,660,735 for, 535,395 against, 9,058 abstained, 55 not voted.

FOR
FOR: 14,660,735AGAINST: 535,395ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Richard Giltner” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,078,1703,193 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street1,733487,778 00Against
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Elect Director: Tommy Thompson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 35,012,786AGAINST: 1,192,155

Prior year: 96.0% for (June 26, 2025 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 151 asset managers

Description as filed by funds: Election of Directors: Tommy Thompson

United Therapeutics Corporation’s own tally for this item (“Elect Director: Tommy Thompson”): 35,012,786 for, 1,192,155 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 151 asset managers below reported 15,177,216 for, 18,914 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,177,216AGAINST: 18,914ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Election of Directors: Tommy Thompson” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3594 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,48724 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 151 asset managers. All 151 are in the interactive database (link above).

Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 6 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST
FOR: 25,872,075AGAINST: 10,070,290

Prior year: 91.8% for (June 26, 2025 meeting) ▼ 19.9 pts

Details: description as filed, official tally, votes by 184 asset managers

Description as filed by funds: Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.

United Therapeutics Corporation’s own tally for this item (“3. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan”): 25,872,075 for, 10,070,290 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 146 asset managers voting on “Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,080,806557 10For
BlackRock2,961,5810 00For
Fidelity1,456,28160,390 00For
Invesco557,0000 00For
State Street488,964547 00For
Charles Schwab295,8790 00For
Capitol Series Trust3,500271,736 00Against
Pacer Funds Trust0239,327 00Against
Lord Abbett230,3720 00For
First Trust0229,981 00Against
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price215,3437,100 00For
Franklin Custodian Funds200,0000 00For
Dimensional0177,305 00Against
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock80,60654,104 00Mixed
Thrivent0111,740 00Against
JPMorgan99,4810 00For
Jackson National74,1367,428 00Mixed
AQR073,127 00Against
ADVISORS SERIES TRUST070,900 00Against
American Century066,480 00Against
Equitable66,2600 00For
Allspring060,341 00Against

Fund voting reports, all 146 managers: 13,182,911 for, 1,904,238 against, 1 abstained, 55 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 37 asset managers voting on “Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP00 257,9470Abstain
BOWEN HANES & CO INC114,4600 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.070,900 00Against
Erste Asset Management GmbH027,009 00Against
Cardano Risk Management B.V.15,8060 00For
L2 Asset Management, LLC14,0050 00For
Apollon Wealth Management, LLC8,7440 00For
Vident Advisory, LLC5,4940 00For
Dorsey Wright & Associates04,810 00Against
EVOLVE PRIVATE WEALTH, LLC4,7460 00For
AUGUSTINE ASSET MANAGEMENT INC4,1510 00For
LEUTHOLD GROUP, LLC2,9370 00For
Clark Capital Management Group, Inc.2,0270 00For
Trail Ridge Investment Advisors, LLC1,6200 00For
Summit Trail Advisors, LLC0747 00Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC0519 00Against
Hendershot Investments Inc.0200 00Against
ZACKS INVESTMENT MANAGEMENT14147 00Mixed
WRIGHT INVESTORS SERVICE INC1060 00For
Royal Capital Wealth Management, LLC1030 00For
Sound View Wealth Advisors Group, LLC1000 00For
Empirical Asset Management, LLC930 00For
Holcombe Financial, Inc.060 00Against
Biltmore Family Office, LLC270 00For
Keel Point, LLC025 00Against

Institutional-manager reports, all 37 managers: 174,558 for, 104,417 against, 257,947 abstained, 7 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Advisory resolution to approve executive compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 12 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 35,152,059AGAINST: 1,048,505

Prior year: 95.6% for (June 26, 2025 meeting) ▲ 1.5 pts

Details: description as filed, official tally, votes by 705 asset managers

Description as filed by funds: Advisory resolution to approve executive compensation.

United Therapeutics Corporation’s own tally for this item (“2. An advisory resolution to approve executive compensation”): 35,152,059 for, 1,048,505 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of United Therapeutics Corporation’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Compensation” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 147 asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,081,3602 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,5110 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price215,3437,100 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National76,5035,061 00Mixed
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
American Century066,480 00Against
Equitable66,2600 00For
Allspring60,3410 00For

Fund voting reports, all 147 managers: 14,987,550 for, 106,629 against, 9,058 abstained, 55 not voted, 27 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 587 asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Avoro Capital Advisors LLC1,950,0830 00For
BlackRock1,860,402293 00For
Wellington1,702,7730 00For
State Street1,674,8130 00For
Renaissance1,297,7620 00For
GEODE CAPITAL MANAGEMENT, LLC1,228,2140 00For
Janus Henderson1,085,9280 00For
Invesco611,1800 00For
ASSETMARK, INC497,98260 00For
Fidelity496,6300 00For
DEERFIELD MANAGEMENT COMPANY, L.P.457,0000 00For
AQR384,1470 00For
T. Rowe Price345,44915,310 00For
Northern Trust345,5240 00For
Vanguard333,6420 00For
MELLON INVESTMENTS Corp329,8230 00For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC318,2250 00For
Swedbank Robur Fonder AB314,5140 00For
BAILLIE GIFFORD OVERSEAS LTD305,3260 00For
Charles Schwab301,8980 00For
FULLER & THALER ASSET MANAGEMENT, INC.284,2370 00For
LORD, ABBETT & CO. LLC264,9330 00For
PICTET ASSET MANAGEMENT SA259,3140 00For
Eversept Partners, LP257,9470 00For
FRANKLIN ADVISERS INC234,5760 00For

Institutional-manager reports, all 587 managers: 24,162,612 for, 754,137 against, 1,357 abstained, 6,559 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 35,753,887AGAINST: 1,647,415

Prior year: 94.8% for (June 26, 2025 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 150 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.

United Therapeutics Corporation’s own tally for this item (“4. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026”): 35,753,887 for, 1,647,415 against, per its Form 8-K filed June 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 150 asset managers below reported 15,168,787 for, 12,048 against, 9,058 abstained, 55 not voted.

FOR
FOR: 15,168,787AGAINST: 12,048ABSTAIN: 9,058NOT VOTED: 55
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at United Therapeutics Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,078,1753,188 00For
BlackRock2,961,5810 00For
Fidelity1,516,6710 00For
Invesco557,0000 00For
State Street489,48724 00For
Charles Schwab295,8790 00For
Capitol Series Trust275,2360 00For
Pacer Funds Trust239,3270 00For
Lord Abbett230,3720 00For
First Trust229,9810 00For
JANUS INVESTMENT FUND227,0580 00For
T. Rowe Price222,4430 00For
Franklin Custodian Funds200,0000 00For
Dimensional177,3050 00For
TIAA155,9200 00For
Hartford142,3610 00For
John Hancock134,7100 00For
Thrivent111,7400 00For
JPMorgan99,4810 00For
Jackson National81,5640 00For
AQR73,1270 00For
ADVISORS SERIES TRUST70,9000 00For
TOCQUEVILLE ASSET MANAGEMENT L.P.70,9000 00For
American Century66,4800 00For
Equitable66,2600 00For

Showing the 25 largest of 150 asset managers. All 150 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 26, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest United Therapeutics Corporation shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 42,446,733 shares outstanding at the time of that meeting.

Fund voting reports: top United Therapeutics Corporation shareholders by shares voted on “Advisory resolution to approve executive compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 11.97%
2BlackRock 6.98%
3Fidelity 3.57%
4Invesco 1.31%
5State Street 1.15%
6Charles Schwab 0.70%
7Capitol Series Trust 0.65%
8Pacer Funds Trust 0.56%
9Lord Abbett 0.54%
10First Trust 0.54%
Institutional-manager reports: top United Therapeutics Corporation shareholders by shares voted on “Advisory resolution to approve executive compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Avoro Capital Advisors LLC 4.59%
2BlackRock 4.38%
3Wellington 4.01%
4State Street 3.95%
5Renaissance 3.06%
6GEODE CAPITAL MANAGEMENT, LLC 2.89%
7Janus Henderson 2.56%
8Invesco 1.44%
9ASSETMARK, INC 1.17%
10Fidelity 1.17%

Reported United Therapeutics Corporation holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

United Therapeutics Corporation holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock5,399,649 12.72%Form 13F, quarter ended March 31, 2026
Vanguard Group4,176,016 9.84%Form 13F, quarter ended March 31, 2026
Martine Rothblatt2,867,290 6.76%Proxy statement (DEF 14A), table as of April 10, 2026
Avoro Capital Advisors LLC2,858,888 6.74%Proxy statement (DEF 14A), table as of April 10, 2026
ROTHBLATT MARTINE A2,333,721 5.50%Schedule 13G, filed August 14, 2026
Wellington Management2,264,247 5.33%Form 13F, quarter ended March 31, 2026
State Street1,843,963 4.34%Form 13F, quarter ended March 31, 2026
Renaissance Technologies1,787,019 4.21%Form 13F, quarter ended March 31, 2026
Citadel Advisors697,843 1.64%Form 13F, quarter ended March 31, 2026
Invesco608,367 1.43%Form 13F, quarter ended March 31, 2026

Percentages above are of 42,446,733 shares outstanding, as reported by United Therapeutics Corporation on its Form 10-Q dated April 29, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At United Therapeutics Corporation's shareholder meeting held June 26, 2026, in the 2025-2026 proxy season, 708 asset managers reported votes on at least one of its 15 ballot items in their SEC Form N-PX filings, covering 11,575 separate fund positions. On the most widely held item on that ballot — Advisory resolution to approve executive compensation. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: United Therapeutics Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 29, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from United Therapeutics Corporation’s 10-Q dated April 29, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

United Therapeutics Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “United Therapeutics (UTHR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/united-therapeutics-corp/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.